A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes

A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes

Background: In 2015, Ikervis® became the only EMA-approved cyclosporine A (CsA) eye-drop for the treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. Since the 1980s, CsA has been used empirically for ocular conditions...

Full description

Saved in:
Bibliographic Details
Main Author: Yasmina Iffet Eroglu
Format: Article
Language:English
Published: MDPI AG 2017-01-01
Series:Journal of Market Access & Health Policy
Subjects:
cationic emulsion
cyclosporine A
ocular delivery
dry eye disease
severe keratitis
ophthalmology
topical
drug compounding
composite end point
reimbursement
Online Access:http://dx.doi.org/10.1080/20016689.2017.1336043
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://dx.doi.org/10.1080/20016689.2017.1336043

Similar Items